642 related articles for article (PubMed ID: 2906281)
1. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
2. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
Tötterman TH; Karlsson FA; Bengtsson M; Mendel-Hartvig I
N Engl J Med; 1987 Jan; 316(1):15-22. PubMed ID: 2946953
[TBL] [Abstract][Full Text] [Related]
3. Activated T cells in Graves' disease before treatment.
Kennedy R; Di Mario U; Pozzilli P; Guy K; Leonardi M; Sensi M; Andreani D
Clin Exp Immunol; 1985 Feb; 59(2):377-82. PubMed ID: 3156702
[TBL] [Abstract][Full Text] [Related]
4. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
5. The decrease in non-specific suppressor T lymphocytes in female hyperthyroid Graves' disease is secondary to the hyperthyroidism.
Gerstein HC; Rastogi B; Iwatani Y; Iitaka M; Row VV; Volpé R
Clin Invest Med; 1987 Jul; 10(4):337-44. PubMed ID: 2888555
[TBL] [Abstract][Full Text] [Related]
6. Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease.
Aust G; Lehmann I; Heberling HJ
Exp Clin Endocrinol Diabetes; 1996; 104(1):50-8. PubMed ID: 8750571
[TBL] [Abstract][Full Text] [Related]
7. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
Corrales JJ; López A; Ciudad J; Orfao A
J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
[TBL] [Abstract][Full Text] [Related]
8. Reduced ecto-5'-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity.
Salazar-Gonzalez JF; Moody DJ; Giorgi JV; Martinez-Maza O; Mitsuyasu RT; Fahey JL
J Immunol; 1985 Sep; 135(3):1778-85. PubMed ID: 2991373
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
10. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
11. Correlation of activated monocytes or B cells with T lymphocyte subsets in patients with Graves' disease.
González A; Calleja A; Santiago E; De Miguel C; López-Zabalza MJ; López-Moratalla N
Int J Mol Med; 1998 Jan; 1(1):95-103. PubMed ID: 9852205
[TBL] [Abstract][Full Text] [Related]
12. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry.
Atkinson K
Bone Marrow Transplant; 1986 Dec; 1(2):121-32. PubMed ID: 2971408
[TBL] [Abstract][Full Text] [Related]
13. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease.
Eguchi K; Ueki Y; Shimomura C; Otsubo T; Nakao H; Migita K; Kawakami A; Matsunaga M; Tezuka H; Ishikawa N
J Immunol; 1989 Jun; 142(12):4233-40. PubMed ID: 2542405
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of human T lymphocyte subsets distinguished by monoclonal anti-leu-8.
Kansas GS; Wood GS; Fishwild DM; Engleman EG
J Immunol; 1985 May; 134(5):2995-3002. PubMed ID: 3156924
[TBL] [Abstract][Full Text] [Related]
16. Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis.
Misaki T; Konishi J; Nakashima T; Iida Y; Kasagi K; Endo K; Uchiyama T; Kuma K; Torizuka K
Clin Exp Immunol; 1985 Apr; 60(1):104-10. PubMed ID: 3891164
[TBL] [Abstract][Full Text] [Related]
17. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
Charreire J; Karsenty G; Bouchard P; Schaison G
Clin Exp Immunol; 1984 Sep; 57(3):633-8. PubMed ID: 6147216
[TBL] [Abstract][Full Text] [Related]
18. Analysis of recently activated, memory and naive lymphocyte T subsets in the peripheral blood of patients with Graves' disease and insulin-dependent diabetes mellitus.
Kretowski A; Myśliwiec J; Turowski D; Wysocka J; Kinalska I
Rocz Akad Med Bialymst; 1999; 44():226-34. PubMed ID: 10697437
[TBL] [Abstract][Full Text] [Related]
19. Increase of peripheral B lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Kabutomori O; Asari S; Motoi S; Miyai K; Kumahara Y
Clin Exp Immunol; 1980 Oct; 42(1):33-40. PubMed ID: 6970099
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte profiles in patients with chronic low back pain enrolled in a clinical trial.
Brennan PC; Graham MA; Triano JJ; Hondras MA; Anderson RJ
J Manipulative Physiol Ther; 1994 May; 17(4):219-27. PubMed ID: 8046277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
